NEA invests in promising companies across the life sciences spectrum, at all stages of development. We focus on novel therapeutics in major disease areas, with selected investments in diagnostics and platforms to optimize patient therapy and drug discovery, development and delivery. Additionally, we focus on medical device investments across a broad range of traditional clinical areas and investment stages while eyeing potential new markets created by
technological advancements or other market trends.

In the rapidly changing landscape of today’s U.S. healthcare delivery system, one thing that remains the same is NEA’s commitment to its digital health practice, which has evolved into a platform model active across all stages of investment.